title: [Monitoring of minimal residual disease in patients with acute promyelocytic leukemia].
abstract: OBJECTIVE
  To study efficacy of different programs of maintenance therapy, to create the program of differential therapy of minimal residual disease (MRD) and molecular recurrences at all stages of acute promyelocytic leukemia (APL) basing on the results of monitoring.
  
  
  METHODS
  A total of 76 APL patients entered the trial. They received therapy by the protocols APL-97/98, APL-01, AIDA, 5D. Expression of chymeric oncogen PML/RARa in the disease onset was estimated by bone marrow and/or peripheral blood examination with RT-PCR. The study of chymeric oncogen PML/RARa was made once in two months.
  
  
  RESULTS
  The program of differential therapy of APL is proposed on the basis of molecular-biological monitoring of expression of chymeric oncogen PML/RARa. The results of molecular monitoring of MRD correlated with development of molecular and hematological recurrences. Therapeutic policy is determined after diagnosis of molecular recurrence. Further therapy of APL is determined which allows a rise in overall and recurrence-free survival of the patients.
  
  
  CONCLUSIONS
  The efficacy of maintenance therapy only with cytostatic drugs or their combination with ATRA is similar. The response to biological therapy with ATRA plus interferon-alpha is not sufficient. Molecular recurrences--probable or documented--are detected in maintenance therapy 2 months earlier, on the average, than hematological ones. Changes in the treatment policy in registration of molecular recurrence significantly diminish probability of hematological recurrence (from 36 to 0%, p = 0.001.
authors.forename: E N
authors.initials: EN
authors.lastname: Shuravina
authors.forename: E N
authors.initials: EN
authors.lastname: Parovichnikova
authors.forename: I A
authors.initials: IA
authors.lastname: Demidova
authors.forename: A V
authors.initials: AV
authors.lastname: Misiurin
authors.forename: V G
authors.initials: VG
authors.lastname: Isaev
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Ol'shanskaia
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000097:blood*; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein